Gujarat Themis Biosyn Q1 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹5,074 Cr
- P/E
- 104.22
- ROE
- 17.41%
- PEG
- -14.94
- Price to sales
- 29.21
- Debt to equity
- 0.56
- 52W high / low
- ₹453 / ₹227
- Sales growth (5Y)
- 12.86%
- EBITDA margin
- 47.43%
- Net profit margin
- 28.15%
- Promoter holding
- 59.33%
- Sales (last year)
- ₹174 Cr
Incorporated in 1981, Gujarat Themis Biosyn Ltd manufactures and sells finished Active Pharmaceutical Ingredients products by fermentation process[1]
Guidance scorecard · Q1 FY27 call
What Gujarat Themis Biosyn's management guided
and where it ranks in Pharmaceuticals & Biotechnology
Pharmaceuticals & Biotechnology
RevenueQ1 FY27 call
10–20%- GTBL aims to grow its top line on a high-teen percentage basis over the next 3 to 5 years.
- With expanded capacity investments, the company expects increasing asset turns and quarter-on-quarter growth in revenues.
- The integration of recent acquisitions like MicroBiopharm and Sanofi’s portfolio is expected to add significant top-line and earnings growth.
- MicroBiopharm acquisition will enable GTBL to enter higher value fermentation-based CDMO space, expanding capabilities in immunosuppressants, oncology, peptides, plasmids, precision fermentation, enzyme engineering, and ADCs.
- Sanofi portfolio acquisition secures existing bread-and-butter APIs and opens up formulations, improving margin and revenue through better distribution and integration of API production.
2 more points from Gujarat Themis Biosyn's call on revenue
Create a free account to keep reading this call
MarginsQ1 FY27 call
FlatSee what Gujarat Themis Biosyn said on margins — free account, 30 seconds.
CapexQ1 FY27 call
Planned- Most of the capex is already completed by the company with only INR10-15 crores left for last mile completion in FY27, along with some maintenance capex totaling around INR20 crores for the year.
- Over the last 3 years, incremental investment of around INR370 crores in gross block, including new fermentation facility, API facility, new R&D infrastructure, and hybrid power project.
- Focus on expansion projects execution and integrating recent acquisitions to commercialize new capabilities, broaden product portfolio while maintaining strong financial performance.
- Additional fermentation capacity expansion (practically doubled capacity), fully operational by end of August 2026, enabling increase in API manufacturing capabilities.
2 more points from Gujarat Themis Biosyn's call on capex
Create a free account to keep reading this call
FundraisingQ1 FY27 call
PlannedSee what Gujarat Themis Biosyn said on fundraising — free account, 30 seconds.
Order bookQ1 FY27 call
- Sachin Patel mentioned consistently being sold out in terms of capacity over the past few years, implying strong demand.
- The company has seen robust increase in sales volumes and a healthy demand outlook for products as per Q1 FY27 performance.
- Integration of recent acquisitions like MicroBiopharm and Sanofi portfolio is expected to lead to new projects and add to revenues.
2 more points from Gujarat Themis Biosyn's call on the order book
Create a free account to keep reading this call
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Gujarat Themis Biosyn latest results (Mar 2026)
Revenue
₹44 Cr
+16% YoY
Net profit
₹11 Cr
-8% YoY
Operating margin
44%
EPS
₹1
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹3,041 Cr | 33.1 | |
| 2 | 40%+ | Up 2%+ | ₹492 Cr | 19.6 | |
| 3 | 40%+ | Up 0–2% | ₹234 Cr | 17.8 | |
| 4 | 40%+ | Flat | ₹18,347 Cr | — | |
| 5 | 40%+ | Flat | ₹8,432 Cr | 32.4 | |
| 6 | 40%+ | Flat | ₹4,295 Cr | — |
Sign up free to see every company in the sector ranking and track Gujarat Themis Biosyn.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingGujarat Themis Biosyn announcements
All announcements →- Fundraise / allotmentNotableGujarat Themis Biosyn Limited announces dividend, fund raise, and AOA amendment
- Fundraise / allotmentNotableGujarat Themis Biosyn Ltd allots ₹585 crore NCDs via private placement on 16-09-2026
- Fundraise / allotmentNotableGujarat Themis Biosyn approves issuance of Non-Convertible Debentures up to ₹585 Cr
- Fundraise / allotmentNotableGujarat Themis Biosyn Limited closes QIP, approves 2,11,86,440 shares at ₹354 each
Financials of Gujarat Themis Biosyn
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Gujarat Themis Biosyn
Quarterly Results
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 28 | 50 | 40 | 39 | 42 | 39 | 35 | 40 | 38 | 36 | 42 | 43 | 44 |
| Expenses + | 13 | 26 | 23 | 21 | 21 | 20 | 19 | 21 | 22 | 22 | 21 | 22 | 25 |
| Operating Profit | 14 | 24 | 17 | 18 | 21 | 19 | 15 | 19 | 16 | 14 | 21 | 21 | 19 |
| OPM % | 52% | 47% | 42% | 46% | 50% | 48% | 44% | 48% | 42% | 39% | 49% | 49% | 44% |
| Other Income + | 2 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 3 | 4 | 4 |
| Profit before tax | 16 | 24 | 17 | 18 | 21 | 18 | 14 | 17 | 16 | 12 | 19 | 17 | 14 |
| Tax % | 25% | 26% | 26% | 26% | 24% | 26% | 26% | 25% | 25% | 25% | 24% | 26% | 24% |
| Net Profit + | 12 | 18 | 13 | 13 | 16 | 13 | 11 | 13 | 12 | 9 | 14 | 12 | 11 |
| EPS in Rs | 1.07 | 1.63 | 1.15 | 1.19 | 1.46 | 1.21 | 0.97 | 1.19 | 1.10 | 0.83 | 1.31 | 1.14 | 1.00 |
Financials of Gujarat Themis Biosyn
Profit & Loss
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 31 | 33 | 36 | 39 | 41 | 85 | 91 | 115 | 148 | 170 | 151 | 166 |
| Expenses + | 25 | 27 | 30 | 33 | 34 | 53 | 50 | 57 | 75 | 91 | 81 | 90 |
| Operating Profit | 7 | 6 | 6 | 6 | 7 | 32 | 40 | 58 | 74 | 79 | 70 | 76 |
| OPM % | 21% | 19% | 17% | 16% | 18% | 37% | 45% | 51% | 50% | 46% | 46% | 46% |
| Other Income + | -0 | 0 | 0 | 0 | 2 | 2 | 3 | 4 | 7 | 4 | 2 | 2 |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 3 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 3 | 4 | 5 | 13 |
| Profit before tax | 5 | 5 | 5 | 5 | 8 | 31 | 41 | 59 | 77 | 79 | 66 | 62 |
| Tax % | 0% | 0% | 10% | 20% | 22% | 24% | 26% | 26% | 25% | 25% | 26% | 25% |
| Net Profit + | 5 | 5 | 4 | 4 | 6 | 24 | 30 | 44 | 58 | 59 | 49 | 47 |
| EPS in Rs | 0.42 | 0.42 | 0.40 | 0.36 | 0.59 | 2.17 | 2.77 | 4.00 | 5.32 | 5.43 | 4.48 | 4.28 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 10% | 0% | 37% | 14% | 12% | 15% | 16% |
Financials of Gujarat Themis Biosyn
Balance Sheet
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 11 | 11 |
| Reserves | -8 | -3 | 1 | 5 | 11 | 35 | 63 | 96 | 142 | 194 | 237 | 254 |
| Borrowings + | 6 | 3 | 4 | 1 | 6 | 8 | 5 | 1 | 0 | 3 | 30 | 71 |
| Other Liabilities + | 9 | 8 | 9 | 8 | 8 | 14 | 14 | 18 | 17 | 17 | 22 | 41 |
| Total Liabilities | 15 | 15 | 21 | 20 | 33 | 64 | 88 | 122 | 166 | 221 | 301 | 377 |
| Fixed Assets + | 10 | 9 | 11 | 11 | 15 | 17 | 19 | 19 | 33 | 38 | 41 | 162 |
| CWIP | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 13 | 21 | 91 | 184 | 132 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets + | 5 | 5 | 11 | 10 | 17 | 47 | 67 | 90 | 113 | 92 | 76 | 82 |
| Total Assets | 15 | 15 | 21 | 20 | 33 | 64 | 88 | 122 | 166 | 221 | 301 | 377 |
Financials of Gujarat Themis Biosyn
Cash Flows
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 3 | 4 | 3 | 6 | 1 | 1 | 11 | 40 | 39 | 64 | 91 | 49 |
| Cash from Investing Activity + | -0 | -1 | -3 | -1 | -6 | -3 | -2 | -30 | -20 | -55 | -112 | -172 |
| Cash from Financing Activity + | -3 | -3 | -0 | -4 | 5 | 2 | -5 | -14 | -13 | -9 | 26 | 115 |
| Net Cash Flow | -1 | -0 | 0 | 1 | 0 | -0 | 3 | -4 | 6 | 0 | 5 | -9 |
| Free Cash Flow | 2 | 3 | 0 | 5 | -5 | -3 | 7 | 26 | 16 | -10 | -25 | -124 |
| CFO/OP | 44% | 73% | 57% | 99% | 25% | 24% | 51% | 94% | 81% | 107% | 154% | 79% |
Financials of Gujarat Themis Biosyn
Ratios
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 28 | 24 | 71 | 26 | 52 | 87 | 59 | 80 | 44 | 58 | 76 | |
| Inventory Days | 78 | 194 | 144 | 255 | 201 | 33 | 75 | |||||
| Days Payable | 947 | 240 | 84 | 145 | 131 | 99 | 218 | |||||
| Cash Conversion Cycle | 28 | 24 | 71 | -844 | 52 | 41 | 119 | 189 | 114 | -7 | -67 | |
| Working Capital Days | -76 | -70 | -42 | -43 | -58 | 42 | 80 | 155 | 91 | 50 | 46 | |
| ROCE % | 121% | 81% | 55% | 42% | 45% | 84% | 67% | 67% | 61% | 45% | 27% |
Guidance history
How Gujarat Themis Biosyn's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q1 FY27 call → | 10–20% | Flat | Planned | Planned | — |
| Q2 FY24 call → | 20–40% | Flat | Planned | Planned | — |
| Q3 FY23 call → | 20–40% | Flat | Planned | — | — |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Momentum score · price trend
52 out of 100 — Steady
Over the past year its share price has moved roughly in the middle of the stocks we track.
| Period | Share price change | Better than … of 1,937 stocks |
|---|---|---|
| Last 12 months | −13.6% | 37% |
| Last 6 months | +5.0% | 54% |
| Last 3 months | +11.4% | 79% |
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,937 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Gujarat Themis Biosyn: 0.4 × 37 + 0.4 × 54 + 0.2 × 79 = 52.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 13 Nov 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Gujarat Themis Biosyn: frequently asked questions
What is Gujarat Themis Biosyn share price today?
Gujarat Themis Biosyn last traded at ₹388.65, with a market capitalisation of ₹5,074 Cr and a P/E ratio of 104.2.
What were Gujarat Themis Biosyn's latest quarterly results?
For the quarter ended Mar 2026, Gujarat Themis Biosyn reported revenue of ₹44 Cr (+16% year on year) and net profit of ₹11 Cr, with an operating margin of 44%.
Is Gujarat Themis Biosyn's profit growing?
Net profit was ₹11 Cr in Mar 2026 against ₹12 Cr in Mar 2025, a change of -8%.
What is Gujarat Themis Biosyn's EPS?
Gujarat Themis Biosyn's earnings per share for the quarter ended Mar 2026 was ₹1.
What is Gujarat Themis Biosyn's ROE and ROCE?
Gujarat Themis Biosyn's return on equity is 18.8% and its return on capital employed is 23.3%.
Does Gujarat Themis Biosyn pay a dividend?
Yes. Gujarat Themis Biosyn's dividend yield is 0.16% at the current price. The full payout history is on the Gujarat Themis Biosyn dividends page.
Which sector does Gujarat Themis Biosyn belong to?
Gujarat Themis Biosyn is in the Pharmaceuticals & Biotechnology sector. Its peer comparison and sector ranking are on this page.
What did Gujarat Themis Biosyn's management say on the latest earnings call?
Arthneeti's analysis of the Q1 FY27 earnings call covers revenue, margins, capex and fundraising guidance from Gujarat Themis Biosyn's management.
How does Arthneeti AI analyse Gujarat Themis Biosyn?
Arthneeti reads Gujarat Themis Biosyn's earnings call transcripts and filings and scores revenue growth, margins, capex and fundraising, then ranks the company against its sector.
Continue your research
What Gujarat Themis Biosyn's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q2 FY27)
11.67% increase. Key results statement takeaways from Natural Capsules Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Sotac Pharmaceuticals (Q2 FY27)
7,654.95 lakhs; Operating margin ≈ 10.68% for HY Sep 2026 . Key results statement takeaways from Sotac Pharmaceuticals Ltd's Q2 FY27 results statement — and how
- Bio Medica Lab (Q2 FY27)
EBITDA for the quarter:** ₹510 lakhs, up 25% year-on-year (YoY). Key results statement takeaways from Bio Medica Laboratories Ltd's Q2 FY27 results statement —
- Syncom Formulations (India) (Q2 FY27)
Quarterly Revenue (Q2 FY 2026-27 ended 30/09/2026):** ₹14,821.08 lakhs (Unaudited) . Key results statement takeaways from Syncom Formulations (India) Ltd's Q2 F